Supplementary Methods
*** 1,700 50 100 * Capecitabine total daily dose was divided over two daily doses according to standard of care ** For the fixed-dosed cohort was capecitabine administered continuously the whole period of radiotherapy (also on non-radiotherapy days), for the BSA-dosed cohort was capecitabine administered continuous only on days of radiotherapy *** The DOC-regimen was not administered in the fixed-dosed cohort Abbreviations: BC = breast cancer; BSA = body surface area; CAPE = capecitabine; CAPOX = capecitabine combined with oxaliplatin; CRC = colorectal cancer; D = day; HFS = hand-foot syndrome; mono = monotherapy; RT = radiotherapy; Q3W = 3-weekly schedule <0.001 * The administered treatment regimens are described in more detail in supplemental table 1 Abbreviations: BSA = body surface area; CAPE = capecitabine; CAPOX = capecitabine combined with oxaliplatin; HFS = hand-foot syndrome; mono = monotherapy; RT = radiotherapy a Capecitabine-specific toxicity was defined as at least one of the following toxicity scores: diarrhea ≥ 3, HFS ≥ 2, neutropenia ≥ 2 b Clinically relevant events was defined as at least one of the following events due to toxicity: dose reduction, stop with capecitabine, hospital admission * The administered treatment regimens are described in more detail in Apendix table 1 Abbreviations: BSA = body surface area; CAPE = capecitabine; CAPOX = capecitabine combined with oxaliplatin; HFS = hand-foot syndrome; mono = monotherapy; RT = radiotherapy
